This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rick, O. Articles by Beyer, J. Search for Related Content PubMed PubMed Citation Articles by Rick, O. Articles by Beyer, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CIS-DIAMINEDICHLOROPLATINUM ETOPOSIDE IFOSFAMIDE PLATINUM COMPOUNDS TAXOL Medline Plus Health Information Testicular Cancer Testicular Disorders Social Bookmarking                            What's this?

Residual Tumor Resection After High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Cancer

From the Department of Hematology and Oncology, Charité, Campus Mitte; Department of Urology, Krankenhaus Am Urban, Berlin; Department of Hematology and Oncology, Eberhards-Karl Universität, Tübingen; Department of Thoracic Surgery, Dr-Horst-Schmidt Kliniken, Wiesbaden; Department of Urology, Bundeswehrkrankenhaus, Hamburg; and Department of Hematology and Oncology, Philipps Universität, Marburg, Germany

Address reprint requests to J. Beyer, MD, Department of Hematology and Oncology, Philipps Universität Marburg, Baldinger Strasse, 35033 Marburg, Germany; e-mail: joerg.beyer{at}mailer.uni-marburg.de

PURPOSE: To assess the role of residual tumor resection performed after high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ cell tumors (GCT).

PATIENTS AND METHODS: Between July 1987 and October 1999, postchemotherapy resections of residual tumors were performed in 57 patients who had been treated with HDCT for relapsed or refractory GCT and who had achieved a partial remission to this treatment.

RESULTS: Complete resections of residual masses were achieved in 52 (91%) of 57 patients who were rendered disease free; in five (9%) of 57 patients, the resections were incomplete. Resection of a single site was performed in 39 (68%) of 57 patients, and the remaining 18 (32%) of 57 patients required interventions at two or more residual tumor sites. Necrosis was found in 22 (38%) of 57 patients, mature teratoma with or without necrosis was found in nine (16%) of 57 patients, and viable cancer with or without additional necrosis or mature teratoma was found in 26 (46%) of 57 patients. Viable cancer consisted either of residual germ cell or undifferentiated cancer in 22 (85%) of 26 patients, with additional non-GCT histologies in the remaining four patients. Patients with viable cancer had a significantly inferior outcome after surgery compared with patients with necrosis and/or mature teratoma even if all cancer was completely resected. Pulmonary lesions with a diameter of more than 2 cm were the only predictive variable for viable cancer in univariate analysis.

CONCLUSION: Resections of all residual tumors should be attempted in patients with relapsed or refractory GCT and partial remissions after HDCT.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Fizazi, J. Oldenburg, A. Dunant, I. Chen, R. Salvioni, J. T. Hartmann, M. De Santis, G. Daugaard, A. Flechon, U. de Giorgi, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study Ann. Onc., February 1, 2008; 19(2): 259 - 264. [Abstract] [Full Text] [PDF]

				A. Lorch, C. Kollmannsberger, J. T. Hartmann, B. Metzner, I. G.H. Schmidt-Wolf, W. E. Berdel, F. Weissinger, J. Schleicher, G. Egerer, A. Haas, et al. Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group J. Clin. Oncol., July 1, 2007; 25(19): 2778 - 2784. [Abstract] [Full Text] [PDF]

				G. Sonpavde, T. E. Hutson, and B. J. Roth Management of Recurrent Testicular Germ Cell Tumors Oncologist, January 1, 2007; 12(1): 51 - 61. [Abstract] [Full Text] [PDF]